Heart valve calcifications in patients with end‐stage renal disease: Analysis for risk factors

Tarrass, Faissal; Benjelloun, M.C.; Zamd, M.; Medkouri, G.; Hachim, Khadija; Benghanem, M.; Ramdani, B.

doi:10.1111/j.1440-1797.2006.00696.x

Cited by 37 publications

(34 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also in some studies on valve calcification in chronic HD, the prevalence of AVC was higher than that of MVC. 12,13 Therefore, we consider that a substantial proportion of the patients had already had AVC at initiation of HD, and developed MVC after HD. In our study, the prevalence of valve calcification was higher in patients with longer HD duration, although this association was not statistically significant.…”

Section: Discussionmentioning

confidence: 99%

Differences in associated factors between aortic and mitral valve calcification in hemodialysis

et al. 2010

View full text Add to dashboard Cite

Increased prevalence of aortic and mitral valve calcification has been reported in patients on hemodialysis, but it remains unknown whether aortic and mitral valve calcification arise from similar pathogenesis. We detected heart valve calcification using two-dimensional echocardiography, and we related valve calcification to various clinical parameters in patients treated with hemodialysis three times a week for more than 1 year. In 112 patients (77 men and 35 women, age 67±10 years, duration on hemodialysis 95 ± 67 months), aortic and mitral valve calcification were observed in 84 (75.0%) and 58 (51.7%) patients, respectively. Aortic valve calcification was associated with increased age, higher serum calcium, lower serum albumin, lower total cholesterol and higher high-sensitivity C-reactive protein. Multivariate analysis showed that increased age and higher serum calcium were independently associated with aortic valve calcification. Conversely, mitral valve calcification was associated with increased age, higher high-sensitivity C-reactive protein and higher serum b 2 -microglobulin, but not with higher serum calcium. In multivariate analysis, increased age and higher serum b 2 -microglobulin were independently associated with mitral valve calcification. Serum b 2 -microglobulin was associated with longer duration on hemodialysis, malnutrition inflammation (lower serum albumin and higher high-sensitivity C-reactive protein) and dyslipidemia. Considering the results in previous studies showing that the distribution of b 2 -microglobulin amyloid deposition was consistent with that of tissue calcification in patients on hemodialysis, b 2 -microglobulin may have pathogenic roles in valve calcification.

show abstract

Section: Discussionmentioning

confidence: 99%

Differences in associated factors between aortic and mitral valve calcification in hemodialysis

et al. 2010

View full text Add to dashboard Cite

show abstract

“…As in atherosclerosis, the calcification of the valves is not passive, but the result of osteoblastic transformation of resident myofibroblasts in cardiac valvular tissue and the deposition of calcium hydroxyapatite crystals. Elevated phosphorus has been associated with valvular calcification and is the most modifiable potential pathogenic factor in CKD [21,22]. This condition is readily identified by echocardiography and rarely causes significant disease of either valve to warrant valve surgery or replacement.…”

Section: Valvular Diseasementioning

confidence: 99%

Diagnosis of Cardiovascular Disease in Patients with Chronic Kidney Disease

McCullough

Assad²

2012

Blood Purif

View full text Add to dashboard Cite

The major forms of cardiovascular disease including coronary atherosclerosis, valvular disease, myocardial dysfunction, and arrhythmias are observed either alone or in combination in a large fraction of patients with chronic kidney disease (CKD). As CKD progresses, these cardiovascular conditions become more prevalent and severe. The clinical implications of combined heart and kidney disease include challenges in diagnosis and management. In addition, the terminal events in CKD commonly involve one of these four domains of cardiovascular disease. This paper will explore the issue of early diagnosis of heart disease in patients with CKD with the major goal being early intervention to lessen the impact of this comorbidity.

show abstract

“…More commonly, patients report symptoms related to the underlying cause of hyperphosphatemia. Serious effect on the person's nervous and cardiovascular system [2,3]R Rma y occur. Complications include ectopic calcification [4,5], secondary hyperparathyroidism [4]R Ra nd renal osteodystrophy.…”

Section: Introductionmentioning

confidence: 99%

“…Hilliard et al demonstrated that endogenous phosphate interferes with the determination of alkaline phosphates in urine and suggested that the wide variation in serum inorganic phosphate concentrations in diseases such as renal tubular disease or uremia might interfere with alkaline phosphatase measurements in serum [30]. 3 efficacy not affected by co-administration of omeprazole compare to coadministration of famotidine is that omeprazole augmented the phosphate binding capacity of calcium carbonate due to greater intragastric binding of phosphorus by caco3 even if its dissociation were less because although generated in smaller amounts all the calcium ions would be captured by Po4 because fewer protons would be competing with them for phosphate binding while with famotidine it acts on stomach H2 receptors and not affect protons so, greater protons would be competing with calcium ions for phosphate binding and this effect caco3 efficacy.…”

mentioning

confidence: 99%

Comparative Study Between the Effect of Histamine Receptor Antagonists of Type Ii (Famotidine) and Proton Pump Inhibitors (Omeprazole) on the Efficacy of Calcium Carbonate as Phosphate Binder in Haemodialysis Patient

Aboelyazeed

El-Haggar

Okasha

2017

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Objective: The purpose of this study was to compare the effect of famotidine versus omeprazole on the efficacy of calcium carbonate as a phosphate binder in the hemodialysis patient. mo with significant decreased (p<0.05) in serum calcium comparing with pre-treatment. Group III showed no significant change (p>0.05) in serum calcium, phosphorus and parathyroid hormone (PTH) comparing with pre-treatment. Both groups (II and III) showed a significant decrease in alkaline phosphatase (ALP) (p<0.05).

show abstract

Heart valve calcifications in patients with end‐stage renal disease: Analysis for risk factors

Abstract: Findings of the present study are consistent with a role of altered calcium and phosphate metabolism in the pathogenesis of VC in HD patients.

Cited by 37 publications

References 17 publications

Differences in associated factors between aortic and mitral valve calcification in hemodialysis

Differences in associated factors between aortic and mitral valve calcification in hemodialysis

Diagnosis of Cardiovascular Disease in Patients with Chronic Kidney Disease

Comparative Study Between the Effect of Histamine Receptor Antagonists of Type Ii (Famotidine) and Proton Pump Inhibitors (Omeprazole) on the Efficacy of Calcium Carbonate as Phosphate Binder in Haemodialysis Patient

Contact Info

Product

Resources

About